Xilio Therapeutics, Inc. — Director's Dealing 2021

Dec 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-12-22

Reporting Person: Russo Rene (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-22	Stock Option (right to buy)	$13.83	A	100000	Acquired	2031-12-21	Common Stock (100000)	Direct

Footnotes

F1: The option award was granted on December 22, 2021 and shall vest on January 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until December 1, 2026.